Key statistics
As of last trade, Tevogen Bio Holdings Inc (TVGN:NMQ) traded at 1.56, 508.37% above the 52 week low of 0.2556 set on Oct 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.56 |
---|---|
High | 1.70 |
Low | 1.51 |
Bid | 1.55 |
Offer | 1.56 |
Previous close | 1.64 |
Average volume | 5.31m |
---|---|
Shares outstanding | 170.65m |
Free float | 11.27m |
P/E (TTM) | 4.36 |
Market cap | 279.86m USD |
EPS (TTM) | 0.3758 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 19:54 GMT.
More ▼
- Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value
- Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model
- UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials
- Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations
- Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient Affordability
- Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920
- Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support
- Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs
- Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company
- Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity
More ▼